2-(2'-methyl-4'-methoxyphenyl)thiophene | 223674-54-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(2'-methyl-4'-methoxyphenyl)thiophene
• 英文别名: 2-(4-methoxy-2-methylphenyl)thiophene
• CAS: 223674-54-2
• 化学式: C₁₂H₁₂OS
• 分子量: 204.293
• InChiKey: RFPAZMHNTYYDIQ-UHFFFAOYSA-N

物化性质

• 沸点：
  297.5±28.0 °C(Predicted)
• 密度：
  1.107±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  37.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2'-methyl-4'-methoxyphenyl)thiophene 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以81%的产率得到3-methyl-4-(thiophen-2-yl)phenol
  参考文献：
  名称：

  First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases

  摘要：

  STS and 17 beta-HSD1 are attractive targets for the treatment of estrogen-dependent diseases like endometriosis and breast cancer. The simultaneous inhibition of both enzymes appears more promising than blockage of either protein alone. We describe a designed multiple ligand approach resulting in highly potent dual inhibitors. The most interesting compound 9 showed nanomolar IC50 values for both proteins, membrane permeability, and no interference with estrogen receptors. It efficiently reversed E1S- and E1-induced T47D cell proliferation.

  DOI：

  10.1021/acs.jmedchem.7b00062
• 作为产物：
  描述：

  2-溴噻吩 、 4-甲氧基-2-甲基苯硼酸 在 四(三苯基膦)钯 、 caesium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 4.0h， 以90%的产率得到2-(2'-methyl-4'-methoxyphenyl)thiophene
  参考文献：
  名称：

  First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases

  摘要：

  STS and 17 beta-HSD1 are attractive targets for the treatment of estrogen-dependent diseases like endometriosis and breast cancer. The simultaneous inhibition of both enzymes appears more promising than blockage of either protein alone. We describe a designed multiple ligand approach resulting in highly potent dual inhibitors. The most interesting compound 9 showed nanomolar IC50 values for both proteins, membrane permeability, and no interference with estrogen receptors. It efficiently reversed E1S- and E1-induced T47D cell proliferation.

  DOI：

  10.1021/acs.jmedchem.7b00062

文献信息

• Highly Active Palladium Catalysts Supported by Bulky Proazaphosphatrane Ligands for Stille Cross-Coupling:  Coupling of Aryl and Vinyl Chlorides, Room Temperature Coupling of Aryl Bromides, Coupling of Aryl Triflates, and Synthesis of Sterically Hindered Biaryls
  作者：Weiping Su、Sameer Urgaonkar、Patrick A. McLaughlin、John G. Verkade

  DOI：10.1021/ja0450096

  日期：2004.12.1

  R' = i-Bu, 1; R = Bz, R' = i-Bu, 3; R = R' = Bz, 4] for palladium-catalyzed Stille reactions of aryl chlorides is described. Catalysts derived from ligands 1 and 4 efficiently catalyze the coupling of electronically diverse aryl chlorides with an array of organotin reagents. The catalyst system based on the ligand 3 is active for the synthesis of sterically hindered biaryls (di-, tri-, and tetra-ortho

  一族氮杂磷杂环配体 [P(RNCH2CH2)2N(R'NCH2CH2): R = R' = i-Bu, 1; R = Bz, R' = i-Bu, 3; R = R' = Bz, 4] 描述了钯催化芳基氯化物的 Stille 反应。源自配体 1 和 4 的催化剂可有效催化电子不同的芳基氯化物与一系列有机锡试剂的偶联。基于配体 3 的催化剂体系对于合成位阻联芳基化合物（二、三和四邻位取代）具有活性。配体 4 的使用允许芳基溴化物在室温下偶联，并且它还允许芳基三氟甲磺酸酯和氯乙烯参与 Stille 偶联。
• Macrocyclic oximyl hepatitis C protease inhibitors
  申请人：Sun Ying

  公开号：US20070281884A1

  公开（公告）日：2007-12-06

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物I的公式，或其药用可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了乙型肝炎病毒的生命周期，同时也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给患者投予含有本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• A Novel Friedel-Crafts Type Reaction of 2-Chlorothiophene with Some Active Aromatic Compounds
  作者：Tyo Sone、Ryoji Yokoyama、Yohko Okuyama、Kazuaki Sato

  DOI：10.1246/bcsj.59.83

  日期：1986.1

  2-Chlorothiophene (1) was found to easily react with certain active aromatic compounds (2) in the presence of AlCl3 under mild conditions, yielding the corresponding 2-arylthiophenes (3) and 5-chloro-2,2′-bithienyl (5) as the main products. With compounds more reactive than 1, the formation of 3 predominated. Reactions of 1 with aryl alkyl ethers, for example, afforded the corresponding 3 in 44–83%

  发现 2-氯噻吩 (1) 在 AlCl3 存在下在温和条件下很容易与某些活性芳香化合物 (2) 反应，生成相应的 2-芳基噻吩 (3) 和 5-氯-2,2'-二噻吩 (5 ) 为主要产品。对于比 1 更具反应性的化合物，3 的形成占主导地位。例如，1 与芳基烷基醚的反应在一步中以 44-83% 的产率提供了相应的 3。
• MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20070281885A1

  公开（公告）日：2007-12-06

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Wagaw Seble

  公开号：US20090156800A1

  公开（公告）日：2009-06-18

  The present invention relates to a process for the preparation of macrocyclic compounds that are useful as hepatitis C virus (HCV) protease inhibitor compounds.